AVTX
Price:
$10.13
Market Cap:
$106.00M
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phas...[Read more]
Industry
Biotechnology
IPO Date
2015-10-14
Stock Exchange
NASDAQ
Ticker
AVTX
According to Avalo Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 42.52%. This represents a change of -103.81% compared to the average of -1115.02% of the last 4 quarters.
The mean historical ROE of Avalo Therapeutics, Inc. over the last ten years is -888.04%. The current 42.52% ROE has changed -104.79% with respect to the historical average. Over the past ten years (40 quarters), AVTX's ROE was at its highest in in the March 2017 quarter at 460.51%. The ROE was at its lowest in in the June 2024 quarter at -4577.55%.
Average
-888.04%
Median
-135.87%
Minimum
-7957.00%
Maximum
381.66%
Discovering the peaks and valleys of Avalo Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 9.82%
Maximum Annual ROE = 381.66%
Minimum Annual Increase = -549.63%
Minimum Annual ROE = -7957.00%
Year | ROE | Change |
---|---|---|
2023 | -431.87% | -213.16% |
2022 | 381.66% | -204.44% |
2021 | -365.43% | 39.41% |
2020 | -262.13% | 238.23% |
2019 | -77.50% | -59.54% |
2018 | -191.57% | -549.63% |
2017 | 42.61% | -100.54% |
2016 | -7957.00% | 9.82% |
2015 | -80.17% | -231.48% |
2014 | 60.98% | -16.58% |
The current ROE of Avalo Therapeutics, Inc. (AVTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-138.55%
5-year avg
-151.05%
10-year avg
-888.04%
Avalo Therapeutics, Inc.’s ROE is greater than AnaptysBio, Inc. (-287.94%), greater than Arcellx, Inc. (-8.28%), greater than Structure Therapeutics Inc. (-16.40%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than ALX Oncology Holdings Inc. (-93.02%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Molecular Partners AG (-39.16%), greater than Mineralys Therapeutics, Inc. (-55.92%), less than Alzamend Neuro, Inc. (276.87%), greater than Virax Biolabs Group Limited (-115.10%), less than Kiromic BioPharma, Inc. (327.18%), greater than Benitec Biopharma Inc. (-60.28%), greater than Century Therapeutics, Inc. (-66.58%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Miromatrix Medical Inc. (-70.01%), less than ZIVO Bioscience, Inc. (618.61%), greater than Bionomics Limited (-116.12%),
Company | ROE | Market cap |
---|---|---|
-287.94% | $677.65M | |
-8.28% | $4.89B | |
-16.40% | $1.91B | |
-90.19% | $76.81M | |
-93.02% | $74.37M | |
-184.40% | $37.86M | |
-47.95% | $202.87M | |
-24.20% | $83.31M | |
-39.16% | $216.81M | |
-55.92% | $621.09M | |
276.87% | $5.86M | |
-115.10% | $8.73M | |
327.18% | $1.69M | |
-60.28% | $243.54M | |
-66.58% | $102.89M | |
-26.83% | $3.05B | |
-42.45% | $300.00M | |
-26.54% | $730.17M | |
-70.01% | $92.95M | |
618.61% | $74.08M | |
-116.12% | $5.75M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avalo Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Avalo Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Avalo Therapeutics, Inc.'s ROE?
How is the ROE calculated for Avalo Therapeutics, Inc. (AVTX)?
What is the highest ROE for Avalo Therapeutics, Inc. (AVTX)?
What is the 3-year average ROE for Avalo Therapeutics, Inc. (AVTX)?
What is the 5-year average ROE for Avalo Therapeutics, Inc. (AVTX)?
How does the current ROE for Avalo Therapeutics, Inc. (AVTX) compare to its historical average?